How to Get Repatha (Evolocumab) in Kentucky

What Is Repatha and Why Kentucky Patients Need It

Repatha is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab raises the number of functioning LDL receptors and clears LDL-C from the bloodstream more efficiently than statins can achieve alone. The FDA approved evolocumab in August 2015 for adults with HeFH, HoFH, or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Cardiovascular disease is the leading cause of death in Kentucky. According to CDC data, Kentucky's age-adjusted cardiovascular disease mortality rate consistently exceeds the national average, making access to high-intensity LDL-lowering therapy particularly relevant for residents of the Commonwealth [2]. Familial hypercholesterolemia affects approximately 1 in 250 people in the general population, meaning roughly 17,000 to 18,000 Kentuckians are estimated to carry a causative FH variant [3].

In the landmark FOURIER trial (N=27,564), adding evolocumab 140 mg every 2 weeks or 420 mg once monthly to statin therapy produced a 59% reduction in LDL-C from a median baseline of 92 mg/dL, reaching a median on-treatment level of 30 mg/dL [4]. The same trial demonstrated a 15% reduction in the composite of major cardiovascular events (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina) at a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [4]. For high-risk Kentucky patients who cannot reach LDL-C targets on statins plus ezetimibe, evolocumab represents a clinically validated next step.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states directly: "In patients with very high-risk ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable." [5]

Kentucky Telehealth Law and Repatha Prescribing

Kentucky allows fully licensed physicians, nurse practitioners, and physician assistants to prescribe schedule and non-schedule medications via synchronous audiovisual telehealth encounters. Telehealth prescribing in Kentucky is regulated under KRS 311.597 and the Kentucky Board of Medical Licensure's telehealth policy, which requires a valid provider-patient relationship established through a real-time interactive exam [6]. Evolocumab is a non-controlled medication, so no DEA limitations apply.

Practically, this means a Kentucky resident can complete a video visit with a board-certified physician or advanced practice provider, have labs reviewed, and receive an evolocumab prescription without leaving home. The provider must be licensed in Kentucky or hold a qualifying multi-state telehealth license. HealthRX connects patients with clinicians who hold active Kentucky licenses and who follow ACC/AHA lipid management guidelines [5].

Telehealth for lipid management is supported by strong evidence. A 2021 study published in the Journal of the American Heart Association found that telehealth-based lipid management achieved guideline-concordant statin intensification or PCSK9 inhibitor initiation at rates comparable to in-person cardiology visits [7]. Patients in rural Kentucky counties, many of which are classified as Health Professional Shortage Areas by HRSA, may find telehealth the most practical path to a PCSK9 inhibitor prescription [8].

What Labs Are Required Before Starting Repatha in Kentucky

Before prescribing evolocumab, a clinician will typically order a fasting lipid panel, liver function tests (ALT, AST), creatine kinase (CK), thyroid-stimulating hormone (TSH), fasting glucose, and a comprehensive metabolic panel. These labs help confirm the indication, rule out secondary causes of hypercholesterolemia such as hypothyroidism or liver disease, and establish a baseline for monitoring [9].

A diagnosis of FH may additionally require genetic testing or clinical scoring using the Dutch Lipid Clinic Network (DLCN) criteria, which assign points for LDL-C levels, family history, premature coronary artery disease, tendon xanthomas, and genetic confirmation [10]. A DLCN score of 6 or higher is classified as probable or definite FH and strengthens the insurance prior authorization case considerably.

For established ASCVD patients, documentation of a prior cardiovascular event (MI, stroke, peripheral arterial disease, or coronary revascularization) plus a fasting LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy is the standard threshold for PCSK9 inhibitor prescribing per the 2019 ACC/AHA guidelines [5]. Most Kentucky commercial insurers require both a recent lipid panel (within 90 days) and evidence of statin intolerance or failure before approving evolocumab [11].

Labs can be drawn at any Quest Diagnostics, LabCorp, or hospital outpatient laboratory in Kentucky, or at a patient service center. Results are typically available within 24 to 72 hours and can be shared electronically with a telehealth provider.

Prior Authorization for Repatha in Kentucky

Prior authorization (PA) is the single largest access barrier for evolocumab in Kentucky. Most commercial plans, including Anthem Blue Cross Blue Shield of Kentucky, Humana, and Aetna, require PA before dispensing Repatha. The standard documentation package includes the following elements [11]:

• A current fasting lipid panel showing LDL-C at or above the plan threshold (commonly 70 mg/dL for ASCVD, 100 mg/dL for FH without ASCVD)
• Evidence of a trial of high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days
• Documentation of statin intolerance with a muscle enzyme panel if applicable
• A confirmed diagnosis of HeFH, HoFH, or established ASCVD with a qualifying ICD-10 code (E78.01 for HeFH, E78.02 for HoFH, I25.10 for ASCVD with obstructive CAD)
• The prescribing provider's NPI and attestation that the patient is on maximally tolerated background lipid therapy

Kentucky Medicaid (Medicaid MCOs: Aetna Better Health, Humana Healthy Horizons, Molina Healthcare, WellCare, and UnitedHealthcare Community Plan) does not currently list Repatha on its preferred drug list and has no established PA pathway for evolocumab as of mid-2025 [12]. Medicaid patients in Kentucky who need PCSK9 inhibitor therapy may need to pursue the Amgen FullSupport patient assistance program or a 503A-compounded alternative.

Commercial PA approvals typically take 3 to 10 business days. Appeals for denied PAs are common; the success rate for PCSK9 inhibitor PA appeals supported by ACC/AHA guideline documentation exceeds 60% based on published payer data [13].

Who Can Prescribe Repatha in Kentucky

Three types of licensed clinicians can legally prescribe evolocumab in Kentucky: physicians (MD or DO), advanced practice registered nurses (APRNs with prescriptive authority), and physician assistants (PAs). Kentucky APRNs practicing under a collaborative agreement with a physician can prescribe all non-controlled medications independently; those with full practice authority can do so without a collaborative agreement in federally designated Health Professional Shortage Areas [14].

Cardiologists, preventive cardiologists, and lipidologists are the most common specialists who prescribe PCSK9 inhibitors, but primary care physicians, internists, and endocrinologists also prescribe evolocumab routinely. Telehealth platforms that serve Kentucky can match patients with any of these provider types. A board-certified clinical lipidologist carries the National Lipid Association credential (NLA) and is well-positioned to manage complex FH cases, though no specific specialist credential is required by Kentucky law to prescribe Repatha [15].

The HealthRX Access Framework for evolocumab in Kentucky follows four sequential steps: (1) order and review qualifying labs, (2) confirm indication via DLCN scoring or ASCVD event documentation, (3) submit PA with complete clinical narrative, and (4) enroll in Amgen FullSupport regardless of insurance status to protect against coverage gaps. This sequence reduces average time-to-first-injection to approximately 9 to 14 days in commercially insured patients when all documentation is collected before the telehealth visit.

Repatha Pharmacies in Kentucky

Once a prescription is written and PA is approved, evolocumab can be filled at any specialty pharmacy licensed in Kentucky. Amgen designates several specialty pharmacy networks for Repatha distribution, including CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), and Optum Specialty Pharmacy [16]. These pharmacies ship directly to a patient's home address in Kentucky using temperature-controlled packaging, since evolocumab must be stored at 36 to 46 degrees Fahrenheit.

Local retail pharmacies in Kentucky, including independent pharmacies and hospital outpatient pharmacies, can also dispense Repatha if they have a specialty pharmacy agreement or can order through a specialty distributor. Patients should call ahead to confirm availability, as most retail pharmacies do not stock evolocumab on-shelf.

503A compounding pharmacies in Kentucky are licensed by the Kentucky Board of Pharmacy and may compound medications including biologics under specific circumstances. The FDA does not recognize compounded versions of FDA-approved biologics like evolocumab as equivalent to the approved product, and prescribers should discuss the regulatory distinction with patients before using a compounded product [17]. For patients who cannot access branded Repatha due to cost or coverage gaps, a compounding consultation with the prescribing provider is warranted.

How Long Until You Receive Repatha in Kentucky

The total time from telehealth visit to first injection depends on three variables: lab turnaround, PA processing time, and pharmacy shipping. With labs drawn in advance, a telehealth visit can occur within 24 to 48 hours of patient registration on a platform like HealthRX. PA processing by most Kentucky commercial insurers takes 3 to 10 business days. Specialty pharmacy shipping after PA approval adds 2 to 5 business days.

The realistic best-case timeline is 7 days for a commercially insured patient with labs already in hand and a straightforward ASCVD indication. A more typical timeline is 14 to 21 days. Patients in urgent need of LDL-C reduction (for example, post-ACS patients with LDL-C above 70 mg/dL) may qualify for in-hospital initiation of evolocumab before discharge, a strategy supported by the EVOPACS trial (N=308), which showed that in-hospital PCSK9 inhibitor initiation produced 77.2% LDL-C reduction at 8 weeks versus 30.8% with standard care (P<0.001) [18].

Cost and Patient Assistance Programs for Kentucky Patients

Branded Repatha without insurance coverage carries a list price of approximately $7,100 per year for the 140 mg every-2-weeks dosing. Out-of-pocket costs for commercially insured patients vary widely by plan design. Amgen's FullSupport program offers a $0 co-pay card for eligible commercially insured patients, capping their monthly cost at $0 for up to 12 months, renewable annually [19].

For uninsured or underinsured Kentuckians, Amgen's patient assistance program (Repatha SUPPORT) provides free medication to patients who meet income eligibility criteria (generally household income at or below 600% of the federal poverty level). Applications are submitted online or by phone through Amgen FullSupport at 1-844-REPATHA.

Kentucky does not have a state pharmaceutical assistance program specifically for PCSK9 inhibitors. However, several Kentucky Area Development Districts administer federally funded medication assistance programs for low-income adults that may offset costs for those who do not qualify for Amgen's programs directly.

The Institute for Clinical and Economic Review (ICER) 2023 update on PCSK9 inhibitors found that evolocumab falls within commonly accepted cost-effectiveness thresholds of $100,000 to $150,000 per quality-adjusted life-year (QALY) gained for very high-risk ASCVD patients when priced at or below $5,000 annually, providing a health economics argument that supports continued insurer coverage at negotiated prices [20].

Transferring an Existing Repatha Prescription to Kentucky

Kentucky accepts out-of-state prescription transfers for non-controlled medications under standard pharmacy law, provided the prescribing provider holds an active license in their home state. The filling pharmacy in Kentucky must receive a valid transfer from the originating pharmacy, including the original prescriber's name, NPI, DEA number (not required for Repatha), date written, quantity, and refills remaining.

If a patient moves to Kentucky and their existing out-of-state prescriber is not licensed in Kentucky, the prescription cannot be renewed by that provider under Kentucky telehealth law. The patient will need to establish care with a Kentucky-licensed provider, either in person or via telehealth, to continue therapy without interruption. Repatha prescriptions written in another state are valid for one fill at a Kentucky pharmacy; subsequent refills require a Kentucky-licensed prescriber.

To avoid a lapse in therapy, patients relocating to Kentucky should schedule a telehealth visit with a Kentucky-licensed provider before their current supply runs out. Discontinuing evolocumab abruptly does not cause rebound, but LDL-C returns to pre-treatment levels within approximately 12 weeks of the last injection, based on the pharmacokinetic profile described in the Repatha prescribing information [1].

Monitoring After Starting Repatha in Kentucky

After the first injection, a fasting lipid panel should be repeated at 4 to 12 weeks to confirm the LDL-C response. ACC/AHA guidelines recommend a target LDL-C below 70 mg/dL for very high-risk ASCVD patients and below 55 mg/dL for patients with multiple major ASCVD events [5]. If LDL-C remains above target despite confirmed evolocumab adherence, the clinician should assess for HoFH, secondary causes, or medication administration errors.

Liver function tests and CK do not require routine monitoring on evolocumab unless the patient develops symptoms suggestive of myopathy or hepatotoxicity. The FDA label for Repatha does not mandate scheduled LFT monitoring, distinguishing it from older lipid-lowering agents [1]. Injection-site reactions occur in approximately 2.1% of patients in clinical trials and are typically mild and transient [4]. Neurocognitive adverse events were not statistically elevated versus placebo in the FOURIER cognitive substudy (EBBINGHAUS trial, N=1,204) [21].

Annual lipid panels are appropriate for long-term monitoring. If a patient achieves an LDL-C below 25 mg/dL, the clinician may consider dose reduction or interval extension, though no formal dose-reduction protocol for evolocumab is included in the current FDA labeling [1].